BR112017010832A2 - composições de aminoácido para o tratamento de sintomas de doença - Google Patents
composições de aminoácido para o tratamento de sintomas de doençaInfo
- Publication number
- BR112017010832A2 BR112017010832A2 BR112017010832A BR112017010832A BR112017010832A2 BR 112017010832 A2 BR112017010832 A2 BR 112017010832A2 BR 112017010832 A BR112017010832 A BR 112017010832A BR 112017010832 A BR112017010832 A BR 112017010832A BR 112017010832 A2 BR112017010832 A2 BR 112017010832A2
- Authority
- BR
- Brazil
- Prior art keywords
- amino acid
- disease symptoms
- acid compositions
- treating disease
- group
- Prior art date
Links
- 239000000203 mixture Substances 0.000 title abstract 3
- 150000001413 amino acids Chemical class 0.000 title abstract 2
- 201000010099 disease Diseases 0.000 title abstract 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 title abstract 2
- 208000024891 symptom Diseases 0.000 title abstract 2
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 abstract 2
- DCXYFEDJOCDNAF-UHFFFAOYSA-N Asparagine Natural products OC(=O)C(N)CC(N)=O DCXYFEDJOCDNAF-UHFFFAOYSA-N 0.000 abstract 1
- 206010003591 Ataxia Diseases 0.000 abstract 1
- 206010012735 Diarrhoea Diseases 0.000 abstract 1
- 201000011001 Ebola Hemorrhagic Fever Diseases 0.000 abstract 1
- 239000004471 Glycine Substances 0.000 abstract 1
- 208000031886 HIV Infections Diseases 0.000 abstract 1
- 208000037357 HIV infectious disease Diseases 0.000 abstract 1
- 206010019133 Hangover Diseases 0.000 abstract 1
- DCXYFEDJOCDNAF-REOHCLBHSA-N L-asparagine Chemical compound OC(=O)[C@@H](N)CC(N)=O DCXYFEDJOCDNAF-REOHCLBHSA-N 0.000 abstract 1
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 abstract 1
- AGPKZVBTJJNPAG-WHFBIAKZSA-N L-isoleucine Chemical compound CC[C@H](C)[C@H](N)C(O)=O AGPKZVBTJJNPAG-WHFBIAKZSA-N 0.000 abstract 1
- KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 abstract 1
- AYFVYJQAPQTCCC-GBXIJSLDSA-N L-threonine Chemical compound C[C@@H](O)[C@H](N)C(O)=O AYFVYJQAPQTCCC-GBXIJSLDSA-N 0.000 abstract 1
- QIVBCDIJIAJPQS-VIFPVBQESA-N L-tryptophane Chemical compound C1=CC=C2C(C[C@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-VIFPVBQESA-N 0.000 abstract 1
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 abstract 1
- KZSNJWFQEVHDMF-BYPYZUCNSA-N L-valine Chemical compound CC(C)[C@H](N)C(O)=O KZSNJWFQEVHDMF-BYPYZUCNSA-N 0.000 abstract 1
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 abstract 1
- 239000004472 Lysine Substances 0.000 abstract 1
- 206010028980 Neoplasm Diseases 0.000 abstract 1
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 abstract 1
- 241000282898 Sus scrofa Species 0.000 abstract 1
- AYFVYJQAPQTCCC-UHFFFAOYSA-N Threonine Natural products CC(O)C(N)C(O)=O AYFVYJQAPQTCCC-UHFFFAOYSA-N 0.000 abstract 1
- 239000004473 Threonine Substances 0.000 abstract 1
- QIVBCDIJIAJPQS-UHFFFAOYSA-N Tryptophan Natural products C1=CC=C2C(CC(N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-UHFFFAOYSA-N 0.000 abstract 1
- KZSNJWFQEVHDMF-UHFFFAOYSA-N Valine Natural products CC(C)C(N)C(O)=O KZSNJWFQEVHDMF-UHFFFAOYSA-N 0.000 abstract 1
- 229940024606 amino acid Drugs 0.000 abstract 1
- 235000001014 amino acid Nutrition 0.000 abstract 1
- 229960001230 asparagine Drugs 0.000 abstract 1
- 235000009582 asparagine Nutrition 0.000 abstract 1
- 235000003704 aspartic acid Nutrition 0.000 abstract 1
- OQFSQFPPLPISGP-UHFFFAOYSA-N beta-carboxyaspartic acid Natural products OC(=O)C(N)C(C(O)=O)C(O)=O OQFSQFPPLPISGP-UHFFFAOYSA-N 0.000 abstract 1
- 201000011510 cancer Diseases 0.000 abstract 1
- 208000037902 enteropathy Diseases 0.000 abstract 1
- 230000007613 environmental effect Effects 0.000 abstract 1
- 208000033519 human immunodeficiency virus infectious disease Diseases 0.000 abstract 1
- 208000027866 inflammatory disease Diseases 0.000 abstract 1
- 208000028774 intestinal disease Diseases 0.000 abstract 1
- 229960000310 isoleucine Drugs 0.000 abstract 1
- AGPKZVBTJJNPAG-UHFFFAOYSA-N isoleucine Natural products CCC(C)C(N)C(O)=O AGPKZVBTJJNPAG-UHFFFAOYSA-N 0.000 abstract 1
- 230000001225 therapeutic effect Effects 0.000 abstract 1
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 abstract 1
- 239000004474 valine Substances 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
- A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A61K31/404—Indoles, e.g. pindolol
- A61K31/405—Indole-alkanecarboxylic acids; Derivatives thereof, e.g. tryptophan, indomethacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/12—Antidiarrhoeals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Epidemiology (AREA)
- Virology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Hematology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Diabetes (AREA)
- Molecular Biology (AREA)
- Obesity (AREA)
- AIDS & HIV (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
a presente invenção fornece composições terapêuticas e usos das mesmas para o tratamento ou melhora de sintomas de uma doença selecionada a partir do grupo que consiste em: infecção por vírus ebola, infecção por hiv, ataxia, enteropatia ambiental, câncer, ressaca, doença inflamatória e diarreia epidêmica suína. em modalidades preferenciais, a composição inclui uma combinação de um ou mais aminoácidos selecionados a partir do grupo que compreende lisina, ácido aspártico, glicina, isoleucina, treonina, tirosina, valina, triptofano, asparagina e/ou serina.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201462083698P | 2014-11-24 | 2014-11-24 | |
US201562138051P | 2015-03-25 | 2015-03-25 | |
PCT/US2015/061462 WO2016085735A1 (en) | 2014-11-24 | 2015-11-19 | Amino acid compositions for the treatment of symptoms of disease |
Publications (1)
Publication Number | Publication Date |
---|---|
BR112017010832A2 true BR112017010832A2 (pt) | 2017-12-26 |
Family
ID=56074902
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BR112017010832A BR112017010832A2 (pt) | 2014-11-24 | 2015-11-19 | composições de aminoácido para o tratamento de sintomas de doença |
Country Status (8)
Country | Link |
---|---|
US (4) | US20170326088A1 (pt) |
EP (3) | EP3223809A4 (pt) |
JP (1) | JP2017535591A (pt) |
CN (1) | CN107106527B (pt) |
BR (1) | BR112017010832A2 (pt) |
CA (1) | CA2968831A1 (pt) |
MX (1) | MX2017006748A (pt) |
WO (1) | WO2016085735A1 (pt) |
Families Citing this family (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP7267546B2 (ja) * | 2016-10-04 | 2023-05-02 | ユニバーシティ オブ フロリダ リサーチ ファンデーション インコーポレーティッド | アミノ酸組成物及びその使用 |
JP2019043861A (ja) * | 2017-08-30 | 2019-03-22 | アサヒグループホールディングス株式会社 | 乳酸/ピルビン酸比の改善用組成物 |
WO2019070753A1 (en) * | 2017-10-02 | 2019-04-11 | University Of Florida Research Foundation, Incorporated | AMINO ACID COMPOSITIONS AND METHODS FOR TREATING DIARRHEA |
CN112188891A (zh) * | 2018-04-04 | 2021-01-05 | 佛罗里达大学研究基金会公司 | 用于治疗皮肤的组合物 |
IT201800005599A1 (it) * | 2018-05-22 | 2019-11-22 | Lente a contatto morbida | |
CN108434304A (zh) * | 2018-05-23 | 2018-08-24 | 北京雄九医学研究院 | 防癌抗癌中药的制备方法 |
JP2023533617A (ja) * | 2020-07-02 | 2023-08-03 | ユニバーシティ オブ フロリダ リサーチ ファウンデーション,インコーポレイティド | 水分補給を促進するための製剤およびその使用方法 |
US11878073B1 (en) | 2022-09-20 | 2024-01-23 | Entrinsic, LLC | Generation of hydration-targeted formulations and methods of use therein |
Family Cites Families (24)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1994016757A2 (en) | 1991-03-05 | 1994-08-04 | Miris Medical Corporation | Apparatus for providing a timed release of an amount of aerosol medication |
ATE359842T1 (de) | 1991-07-02 | 2007-05-15 | Nektar Therapeutics | Abgabevorrichtung für nebelförmige medikamente |
US6582728B1 (en) | 1992-07-08 | 2003-06-24 | Inhale Therapeutic Systems, Inc. | Spray drying of macromolecules to produce inhaleable dry powders |
US5934272A (en) | 1993-01-29 | 1999-08-10 | Aradigm Corporation | Device and method of creating aerosolized mist of respiratory drug |
US5558085A (en) | 1993-01-29 | 1996-09-24 | Aradigm Corporation | Intrapulmonary delivery of peptide drugs |
US6051256A (en) | 1994-03-07 | 2000-04-18 | Inhale Therapeutic Systems | Dispersible macromolecule compositions and methods for their preparation and use |
KR19980702436A (ko) | 1995-02-23 | 1998-07-15 | 하인쯔 쉬나이더, 미첼 오르진거 | 아미노산 조성물 및 임상용 영양물내에 이의 사용 방법 |
AU6014098A (en) | 1996-12-31 | 1998-07-31 | Inhale Therapeutic Systems | Aerosolized hydrophobic drug |
EP1137805A4 (en) | 1998-11-13 | 2003-03-26 | Los Angeles Childrens Hospital | METHODS FOR FACILITATING VASCULAR GROWTH |
AU2001223942A1 (en) | 2000-01-14 | 2001-07-24 | Olafur Halldorsson | Marine lipid composition for feeding aquatic organisms |
GB0009056D0 (en) | 2000-04-12 | 2000-05-31 | Nestle Sa | Composition comprising free amino acids |
US7063865B2 (en) * | 2002-05-10 | 2006-06-20 | Jeremy Park Jones | Composition and method for substantially reducing the deleterious effects of alcohol on the body |
US20040087490A1 (en) * | 2002-09-20 | 2004-05-06 | Troup John P. | Nutritional compositions |
US20070010459A1 (en) | 2005-01-14 | 2007-01-11 | Ying Liu | Application of asiatic acid and its derivatives to treat pulmonary fibrosis |
EP1864692A1 (en) | 2006-06-07 | 2007-12-12 | Biotempt B.V. | Use of peptides for the control of radiation injury |
JP2011511620A (ja) * | 2007-08-03 | 2011-04-14 | アミノテック アーエス | アミノ酸及びペプチド製品 |
IT1396935B1 (it) | 2009-11-26 | 2012-12-20 | Solartium Entpr Ltd | Uso di una combinazione per il trattamento delle mucositi indotte da radiazioni o da chemioterapici |
IT1397861B1 (it) * | 2010-01-27 | 2013-02-04 | Ambrosialab Srl | Metodo e composizioni per l'applicazione di aminoacidi sulla pelle mediante un mezzo anidro |
GB201012539D0 (en) | 2010-07-27 | 2010-09-08 | Savantium Ltd | Nutritional compositions |
WO2012040707A2 (en) | 2010-09-24 | 2012-03-29 | University Of Florida Research Foundation, Inc. | Materials and methods for improving gastrointestinal function |
CA2831341A1 (en) * | 2011-04-12 | 2012-10-18 | Nestec S.A. | Nutritional compositions including branched chain fatty acids for wound healing |
CA2855854C (en) * | 2011-11-21 | 2020-03-31 | The Institute For Ethnomedicine | L-serine compositions, methods and uses for treating neurodegenerative diseases and disorders |
EA034014B1 (ru) * | 2012-02-08 | 2019-12-19 | Юниверсити Оф Флорида Рисёч Фаундейшн, Инк. | Способ лечения субъекта с диареей, вызванной ротавирусом |
US9987306B2 (en) * | 2012-10-15 | 2018-06-05 | University Of Florida Research Foundation, Inc. | Materials and methods for prevention and treatment of diarrhea and inflammation in the gastrointestinal tract |
-
2015
- 2015-11-19 EP EP15863301.6A patent/EP3223809A4/en not_active Withdrawn
- 2015-11-19 EP EP19200092.5A patent/EP3616689A1/en active Pending
- 2015-11-19 EP EP18202832.4A patent/EP3459540A1/en not_active Withdrawn
- 2015-11-19 JP JP2017528851A patent/JP2017535591A/ja active Pending
- 2015-11-19 BR BR112017010832A patent/BR112017010832A2/pt not_active Application Discontinuation
- 2015-11-19 WO PCT/US2015/061462 patent/WO2016085735A1/en active Application Filing
- 2015-11-19 US US15/528,990 patent/US20170326088A1/en not_active Abandoned
- 2015-11-19 CN CN201580070181.8A patent/CN107106527B/zh active Active
- 2015-11-19 MX MX2017006748A patent/MX2017006748A/es unknown
- 2015-11-19 CA CA2968831A patent/CA2968831A1/en not_active Abandoned
-
2018
- 2018-06-05 US US16/000,792 patent/US10758506B2/en active Active
-
2020
- 2020-08-07 US US16/987,507 patent/US11357747B2/en active Active
-
2022
- 2022-06-10 US US17/837,666 patent/US20220347143A1/en active Pending
Also Published As
Publication number | Publication date |
---|---|
CN107106527B (zh) | 2020-11-24 |
US10758506B2 (en) | 2020-09-01 |
EP3223809A4 (en) | 2018-08-15 |
WO2016085735A1 (en) | 2016-06-02 |
EP3459540A1 (en) | 2019-03-27 |
US20200368194A1 (en) | 2020-11-26 |
US20180289648A1 (en) | 2018-10-11 |
JP2017535591A (ja) | 2017-11-30 |
US20220347143A1 (en) | 2022-11-03 |
US11357747B2 (en) | 2022-06-14 |
EP3223809A1 (en) | 2017-10-04 |
US20170326088A1 (en) | 2017-11-16 |
CN107106527A (zh) | 2017-08-29 |
CA2968831A1 (en) | 2016-06-02 |
EP3616689A1 (en) | 2020-03-04 |
MX2017006748A (es) | 2017-08-28 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
BR112017010832A2 (pt) | composições de aminoácido para o tratamento de sintomas de doença | |
CO2018000104A2 (es) | Moléculas de anticuerpo que se unen a cd22 | |
BR112012018947B1 (pt) | anticorpo anti-caprin-1 monoclonal, composição farmacêutica, combinação farmacêutica e usos de uma composição farmacêutica, de um anticorpo e de uma combinação farmacêutica | |
BR112015019066A2 (pt) | Anticorpos humanos para proteína f do vírus respiratório sincicial e métodos de uso dos mesmos | |
BR112017010893A2 (pt) | análogos de ácidos biliares como agonistas de fxr/tgr5 e métodos de uso dos mesmos | |
BR112012018951B8 (pt) | anticorpo monoclonal, composição farmacêutica, combinação farmacêutica, uso de um anticorpo, uso de uma composição farmacêutica e uso de uma combinação farmacêutica | |
BR112017023161A2 (pt) | composições de ácido obeticólico e métodos de uso | |
BR112017008165A2 (pt) | anticorpos de domínio único direcionados contra antígenos intracelulares | |
BR112014021104A2 (pt) | métodos e composições para o tratamento da doença de huntington | |
CL2018000107A1 (es) | Moléculas de anticuerpo que se unen a cd79 | |
CL2017002082A1 (es) | Nuevas proteínas especificas para pioverdina y pioquelina | |
BR112015010059A2 (pt) | terapia adjuvante com inibidor da quinase da família tec | |
BR112014021102A2 (pt) | Anticorpo, composição farmacêutica, droga de combinação, dna, método de tratamento e uso de anticorpo | |
AR090465A1 (es) | Formas solidas de un profarmaco de nucleotidos de tiofosforamidato | |
BR112017002761A2 (pt) | composições anti-metanogênicas e usos das mesmas | |
BR112014026740A2 (pt) | anticorpo, composição, métodos para tratar um mamífero e para fornecer um anticorpo com adcc realçada, e, uso de um anticorpo | |
CL2017002729A1 (es) | Proteína de unión a rgma y su uso | |
BR112015030356A2 (pt) | métodos de tratamento de uma taupatia | |
BR112015013349A2 (pt) | trieptanoína para o tratamento de deficiência de transportador de glicose 1 | |
BR112014024751A2 (pt) | antígenos de clostridium difficile | |
BR112016015701A2 (pt) | Dendrímero de peptídeo, método de esterilização do mesmo, composição, composição farmacêutica, método de polimerização de fibrinogênio, kit para formação de um hidrogel e hidrogel | |
BR112017000312A2 (pt) | sistema de tratamento da saúde bucal para a aplicação de fosfato de cálcio amorfo, uso de um ou mais aminoácidos básicos, composição, e uso de um ou mais aminoácidos em um sistema de tratamento da saúde bucal | |
BR112016001919A2 (pt) | composição cosmética e processo de tratamento cosmético | |
EA201790558A1 (ru) | Композиция с пониженной иммуногенностью | |
BR112019002458A2 (pt) | composições e métodos para tratar câncer com depleção de arginina e agentes imuno-oncológicos |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
B15I | Others concerning applications: loss of priority | ||
B151 | Others concerning applications: resolution cancelled [chapter 15.31 patent gazette] | ||
B25D | Requested change of name of applicant approved |
Owner name: ENTRINSIC HEALTH SOLUTIONS, INC. (US) |
|
B07D | Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette] |
Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NO 10196/2001, QUE MODIFICOU A LEI NO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUENCIA PREVIA DA ANVISA. CONSIDERANDO A APROVACAO DOS TERMOS DO PARECER NO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDENCIAS CABIVEIS. |
|
B07E | Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette] | ||
B06U | Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette] | ||
B08F | Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette] |
Free format text: REFERENTE A 5A ANUIDADE. |
|
B11B | Dismissal acc. art. 36, par 1 of ipl - no reply within 90 days to fullfil the necessary requirements |